DSC2/3 Antibody (3G130): sc-70994

DSC2/3 Antibody (3G130) is a mouse monoclonal IgG1 antibody that detects DSC2/3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). DSC2/3 is a crucial member of the desmosomal cadherin family, playing a significant role in cell adhesion and maintaining the structural integrity of tissues, particularly in the epidermis. DSC2/3 (3G130) antibody is predominantly localized to specialized adhesion junctions, facilitating strong intercellular connections that are essential for tissue resilience against mechanical stress. DSC2/3 functions not only in structural roles but also in signaling pathways that regulate cell behavior and tissue homeostasis. Notably, DSC2 interacts homophilically with itself and heterophilically with desmoglein 2, which enhances the adhesive properties of desmosomes and contributes to the overall stability of epithelial layers. DSC2/3 presence in various stratified epithelia, including the cervix, tongue, and esophagus, underscores DSC2/3′s vital function in maintaining the integrity of these tissues under physiological and pathological conditions. With robust reactivity and versatility in multiple applications, anti-DSC2/3 antibody (3G130) serves as an invaluable tool for researchers studying cell adhesion mechanisms and desmosomal dynamics.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DSC2/3 Antibody (3G130) References:

1. Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype.  |  Oue, N., et al. 2015. Cancer Sci. 106: 951-8. PMID: 26033320
2. The aberrant expression or disruption of desmocollin2 in human diseases.  |  Sun, C., et al. 2019. Int J Biol Macromol. 131: 378-386. PMID: 30851326
3. CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer.  |  Bębnowska, D., et al. 2020. J Clin Med. 9: PMID: 32560392
4. Androgen downregulates desmocollin-2 in association with induction of mesenchymal transition of breast MDA-MB-453 cancer cells.  |  Ahram, M., et al. 2021. Cytoskeleton (Hoboken). 78: 391-399. PMID: 35023302
5. Weighted correlation network analysis revealed novel long non-coding RNAs for colorectal cancer.  |  Chodary Khameneh, S., et al. 2022. Sci Rep. 12: 2990. PMID: 35194111
6. Ginsenoside Rg1 as a promising adjuvant agent for enhancing the anti-cancer functions of granulocytes inhibited by noradrenaline.  |  Zhu, Y., et al. 2023. Front Immunol. 14: 1070679. PMID: 36817446
7. Validation the role of desmocollin-2 in osteosarcoma based on single cell and bulk RNA seq and experimental analyses.  |  Zeng, J., et al. 2023. J Cancer. 14: 2619-2632. PMID: 37779876
8. A Retrospective View of the Triple-Negative Breast Cancer Microenvironment: Novel Markers, Interactions, and Mechanisms of Tumor-Associated Components Using Public Single-Cell RNA-Seq Datasets.  |  Kim, M., et al. 2024. Cancers (Basel). 16: PMID: 38539508
9. Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.  |  Han, JY., et al. 2024. BMC Cancer. 24: 532. PMID: 38671389
10. MCP-enhanced SOD3 activity inhibits gastric cancer and potentiate chemotherapy via modulating EGFR signaling.  |  Sun, C., et al. 2024. Life Sci. 362: 123358. PMID: 39746602

The preferred DSC2/3 antibody is DSC2/3 Antibody (7G6): sc-53485.